H epatocellular carcinoma (HCC) has had the fastest-rising incidence and mortality among cancers in the United States for many decades. HCC is clinically, molecularly, and biologically heterogeneous and highly resistant to treatment.
(1,2) A major barrier to improving HCC patient outcomes is the incomplete understanding of HCC heterogeneity and its impact on therapeutic intervention. Tumor heterogeneity consists of intertumor (tumor by tumor) and intratumor (within each tumor) heterogeneity. Strong evidence indicates the presence of intertumor heterogeneity as several stable molecular subtypes are found in HCC. (3) (4) (5) (6) (7) However, knowledge on intratumor heterogeneity, especially at the single-cell level in HCC, is limited. (8) The current view is that each primary tumor lesion consists of cells that may differ genetically and epigenetically, which may result in phenotypic heterogeneity unique to each tumor type. (9) Some of these tumor cells, referred to as cancer stem cells (CSCs), are thought to be responsible for generating a heterogeneous tumor lesion and contributing to treatment resistance, tumor relapse, and metastasis. Thus, there is an urgent need to understand intratumor heterogeneity by characterizing tumor cell communities, cellular hierarchy, and their Abbreviations: CD, cluster of differentiation; CD24 biodiversity specific to a particular tumor type with unique clinical features and therapeutic responses.
Intratumor genomic heterogeneity has been recently documented in many tumor types including HCC. (10, 11) Evidence linking intratumor genomic heterogeneity to cancer prognosis has also been noted. (12) One hypothesis is that a tumor lesion is hierarchically organized, with each cell having different roles, which collectively ensure the survival of a given tumor cell community. However, current genomic analyses rely on bulk tissue with mixed tumor cells. Such methods are not robust enough to capture the tumor evolution and cell communities. Currently, it is unclear how various heterogeneous tumor cells cooperate with each other and whether their collective behavior and regulation exist as an efficient community unique to each tumor subtype. Notably, tumor communities are poorly characterized.
The recent development of single-cell genome sequencing technologies has generated many new insights into complex biological systems, including human cancers. (13) Single-tumor cell analysis can provide the level of sensitivity and specificity to understand tumor biology regarding collective behavior and regulation of a given tumor cell community. (14, 15) In this study, we hypothesized that CSC heterogeneity may contribute to a molecular and biological diversity of an HCC cell community and, consequently, patient prognosis. Thus, we conducted a feasibility study by performing single-cell transcriptome analysis to characterize CSC heterogeneity in HCC.
Materials and Methods

CLINICAL SPECIMENS
The Liver Cancer Institute (LCI) and Laboratory of Experimental Carcinogenesis (LEC) cohorts have been described. (4, 16) The study was approved by the institutional review board of the LCI and the National Institutes of Health. For The Cancer Genome Atlas (TCGA) cohort, clinical and RNA-sequencing (RNA-seq) data related to 250 liver HCC samples with available survival data were collected from TCGA (https://cancergenome.nih.gov/). A resected HCC sample was obtained with informed consent from a patient who had undergone resection at the National Institutes of Health Clinical Center, and tissue acquisition procedures were approved by the institutional review board of the National Institutes of Health.
CELL LINES
Human liver cancer cell lines (HuH1 and HuH7) were obtained from the Health Science Research Resources Bank (JCRB0199 and JCRB0403, respectively). Cell line authentication was performed by the National Cancer Institute's Genome Core Laboratory using short tandem repeats analysis. For twodimensional and three-dimensional cultures, the cell lines were cultured with the specific media that have been established for each cell line, as described. (16) 
IMMUNOFLUORESCENCE STAINING
For monolayer cell staining, cells growing on 12-mm coverslips were fixed in formaldehyde 4% (VWR) for 20 minutes at room temperature, washed, and blocked in 1% bovine serum albumin and 2% fetal bovine serum in phosphate-buffered saline, followed by incubation with conjugated primary antibodies against epithelial cell adhesion molecule (EpCAM) (fluorescein isothiocyanate, no. 60136FI; Stemcell Technologies), cluster of differentiation 133 (CD133; allophycocyanin, no. 130-090-854; Miltenyi Biotec), and CD24 (phycoerythrin, no. 555428, BD
ARTICLE INFORMATION:
From the 1 Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; Pharmingen) for 2 hours at room temperature. For spheroid cells, single-cell suspensions of 1,000 cells were seeded in six-well ultra-low attachment microplates (Corning, Corning, NY) and cultured for 2 weeks. Collected spheres were seeded to eight-well chamber slides (Thermo Fisher Scientific, Waltham, MA) and fixed with 4% paraformaldehyde for downstream staining. Images were taken with an LSM 780 confocal microscope (Carl Zeiss, Jena, Germany).
FLOW CYTOMETRY AND SORTING
Cell pellets were resuspended in staining buffer (phosphate-buffered saline [pH 7.2], 0.5% bovine serum albumin, and 2 mM ethylene diamine tetraacetic acid) supplemented with penicillin and streptomycin. The cell suspension was further filtered through a 0.45-lM filter to remove cell aggregates. Antibody staining was performed on ice for 16 minutes. Stained cells were washed of excess unbound antibodies and resuspended in staining buffer. Flow analysis was done on a five-laser BD LSRFortessa (Becton Dickinson) cell analyzer, and single-cell sorting was done using a five-laser BD FACSAria Fusion cell sorter (Becton Dickinson). Forward scatter-height versus forward scatter-width and side scatter-height versus side scatter-width were used to eliminate cell doublets and other aggregates and ensure single-cell sorting. Dead cells were eliminated by excluding Sytox-positive (SYTOX Blue dead cell stain; Thermo Fisher Scientific) cells, which increased the efficiency of sorting robust, live cells for single-cell experiments.
SINGLE-CELL CLONOGENICITY ASSAY AND FLOW ANALYSIS OF SINGLE CELL-DERIVED CELL POPULATIONS
Single cells were directly sorted based on cell surface marker status into 96-well plates with culture medium. After 2-hour incubation, the wells were checked under the microscope to confirm that there was one single cell per well, and the positive wells were recorded and counted. For the clonogenicity assay, single cells were grown for 2 weeks, followed by counting of the number of clones and the cell number found within each single clone. For flow analysis, clones were cultured for 1 month to obtain appropriate cell numbers for analysis. 
DEPArray PROCEDURE
DATA PROCESSING OF SINGLE-CELL RNA-seq FROM THE SMART-seq PLATFORM
Read alignment to the human reference genome GRCH38 and Gencode version 24 was performed using STAR version 2.5.1. (17) RNA quantification was performed using RSEM version 1.2.22. (18) Average mapped reads for the two cell lines are around 6 million reads, while average mapped reads for single cells from the patient biopsy sample are around 4 million reads. All downstream analyses were carried out using R version 3.3.3. Raw data from human embryonic stem cells from GSE69471, (19) mouse endothelial cells (ECs), and adult mouse hematopoietic stem cells (HSCs)-stages T1 and T2 pre-HSCs from the E11 AGM region and mature HSCs from E12 and E14 fetal liver from GSE66954 (20) -were used as reference samples in principal component analysis. All data were median-normalized before further analyses. To combine mouse and human gene expression, genes from the mouse and human genomes were mapped to the gene list from the human and mouse gene coexpression study. (21) Human and mouse genes with the same gene symbols (11, 493) were retained for further analyses. We also investigated the distribution of nonzero data points (transcripts that are "detectable" on the platforms) across all data sets and observed that each data set shows a normal distribution independently within similar ranges as well as together, suggesting that while they are from different platforms, the data show concordant variations (see Supporting Fig. S4A ,B). We did not perform further data transformation due to the relatively small number of sequencing reads, the sparsity of data, and cell population heterogeneity present in single-cell sequencing data as data transformation would significantly decrease the dimension of the data, decrease intrinsic biological variability (especially in low abundant expressed genes), and cause less stable estimation (precise measurement). (22) To generate principal component analysis, we clustered our singlecell data with other groups, including human embryonic stem cells, murine ECs, and murine HSCs without transformation.
SINGLE-CELL RNA-seq USING THE GemCode PLATFORM
The 103 Genomics platform was used to generate gene expression data from single cells from HCC cell lines and the HCC biopsy sample. Briefly, frozen cells were thawed at 378C and washed with phosphatebuffered saline 1 0.04% bovine serum albumin, and approximately 5,000 cells were loaded onto the 103 Genomics Chromium Controller machine for gel beadsin-emulsion generation. During this step, cells were partitioned into the gel beads in emulsion along with Gel Beads coated with oligos. These oligos provide poly-dT sequences to capture mRNAs released after cell lysis inside the droplets, as well as cell-specific and transcriptspecific barcodes (14-bp 103 Barcode and 10-bp Randomer, respectively). mRNA from cell lines and the HCC biopsy sample was prepared using 103 Genomics Chromium Single Cell 3 0 reagent kit (V1 chemistry). Following reverse transcription, complementary DNA containing both barcodes was recovered, purified, and amplified to generate sufficient quantities for library preparation. All three samples were pooled and sequenced in one run NextSeq500 with NextSeq V2 chemistry. The sequencing run was set up as an asymmetric dual index run: read 1 had 98 bp for transcript read, index 1 had 14 bp for cell barcode index read, index 2 had 8 bp for sample index read, and read 2 had 10 bp for unique molecular identifier (UMI). Demultiplex was done, allowing one mismatch in the barcodes.
DATA PROCESSING OF SINGLE-CELL RNA-seq FROM THE GemCode PLATFORM Sample demultiplex, read alignment, and UMI counting and graph-based clustering analysis with t-distributed stochastic neighbor embedding (tSNE) calculation were performed using CellRanger version 1.3.1 (https://support.10xgenomics.com/single-cellgene-expression/software/pipelines/latest/what-is-cellranger). All data processing was done on the National Institutes of Health HPC Biowulf cluster (http://hpc. nih.gov). All other downstream analyses were carried out using R version 3.3.3. In total, 3,847 cells were sequenced from the three cell types, which are not fluorescence-activated cell sorted (FACS) cells. For HuH1, HuH7, and HCC patient cells, 899, 2,088, and 860 cells were sequenced, respectively. After normalization, there were 75,826 mean reads per cell, with 2,703 median genes detected per cell. Finally, 3,649 cells with more than 1,660 UMI counts were retained for further analyses. tSNE analysis and graphbased clustering were performed using the first 10 principal components for projection. Normalized and z-scored expression of selected HCC-specific CSC marker genes were overlaid onto tSNE projection.
Additional methods can be found in the Supporting Information.
Results
PHENOTYPIC AND BIOLOGICAL HETEROGENEITY OF LIVER CSCs
Compelling experimental data indicate the presence of HCC CSCs defined by various cell surface markers, e.g., CD13, CD24, CD44, CD90, CD133, and EpCAM, as the source of tumor initiating cells. (23) These cells are capable of self-renewal, differentiation, and production of heterogeneous tumors. Moreover, the discrete nature of CSCs, defined by CD90 and EpCAM, was noted on bulk tissue. (24) To better define CSC heterogeneity, we performed single-cell analysis. First, we characterized HuH1 and HuH7, two independent and well-defined HCC cell lines, for the presence of CSC properties and heterogeneity. (16, 25) We first characterized commercially available antibodies specific to CD13, CD24, CD44, CD90, CD133, and EpCAM for immunofluorescence and FACS analyses for their abilities to detect different CSC subpopulations. We selected antibodies specific to CD24, CD133, and EpCAM for further studies due to their superior performance in sensitivity and specificity (data not shown). To determine the biological and molecular heterogeneity of CSCs, we first compared different subpopulations of CSCs by examining CSC marker expression in HCC cells cultured in either monolayers or organoids at the single-cell level using confocal imaging analysis (Fig. 1) . Within each cell type, we observed vast heterogeneity of CSC subpopulations in both monolayers (Fig. 1A ) and organoids (Fig. 1B) . Interestingly, some cells express all three markers, but other CSC subpopulations show discrete clusters and seem to not be randomly distributed among a colony of cells.
Next, we isolated distinct CSC subpopulations using a single marker through FACS, plated them onto 96-well plates, and assessed their self-renewal potential. A total of 1,343 single HuH1 cells and 1,134 single HuH7 cells from three independent single-cell sorts were assessed. We found that approximately 15%-20% of marker-positive CSC subpopulations of HuH1 cells and approximately 8%-12% of marker-positive subpopulations of HuH7 cells could divide ( Fig. 2A,B) . Notably, only certain CSC subpopulations seem to divide better when cultured under hypoxia, a condition known to promote stemness. (26) In contrast, approximately 0%-5% of marker-negative cells could divide, consistent with previous findings. (16, 25, 27) We next monitored cell numbers in each colony derived from single marker-expressing cells for a culture period of 2 weeks under normoxia or hypoxia. We found that there was a vast difference in selfrenewal capacities among different CSC subpopulations in both HuH1 and HuH7 cells (Fig. 2C,D) . (Fig. 2E) . Interestingly, surviving marker-negative cells, once expanded, regained a population of mixed CSCs, suggesting that either a few of these cells may not have been truly markernegative or they underwent trans-differentiation from marker-negative to marker-positive cells. These results indicate that distinct CSC subpopulations identified using single-cell surface markers all had a higher selfrenewal capacity compared to marker-negative cells but displayed appreciable biological differences in cell division and responses to hypoxia.
TRANSCRIPTOME LANDSCAPES OF INDIVIDUAL LIVER CSCs AND HETEROGENEITY
To determine if the biological difference among individual marker-expressing CSCs could be linked to different molecular features, we performed single-cell transcriptome analysis using single-cell SMART-Seq. We isolated marker-expressing HuH1 and HuH7 cells by FACS. We also isolated marker-expressing cells (CD133
2 ) from a surgically resected tumor (P1) by DEPArray. We obtained RNA-seq data with an average of 6 million uniquely mapped reads per cell from a total of 118 single cells and pools of 10 or 100 cells. As a control, we first examined levels of marker expression among sorted single cells. We found that marker-positive cells defined by FACS generally had much higher levels of corresponding transcripts than marker-negative cells (Supporting Fig. S1 ), revealing excellent sensitivity of the single-cell RNA transcriptome methodology.
To determine the global transcriptomic diversity of CSCs, we included publicly available single-cell RNA-seq data from human embryonic stem cells, murine ECs, and murine HSCs for comparison. (19, 20) Using principal component analysis, we found that each cell type has a distinct transcriptome because single cells are clustered largely based on their types, without or with batch effect removal ( Fig. 3A; Supporting  Fig. S4C ). In addition, each single cell differs in its transcriptome within a cell community regardless of whether cells are cultured HCC cell lines or freshly isolated tumor cells. However, such a difference was diminished when a pool of 10 or 100 cells was analyzed (Fig. 3A) , indicating that transcriptomic heterogeneity exists at the single-cell level but decreases significantly in cell pools. We observed a greater transcriptomic diversity in HuH7 cells than HuH1 cells based on their marker expression. Moreover, when single HuH7 cells were clustered according to their transcriptome, they could be identified based largely on marker expression (Fig. 3B) . Similar results were obtained in HuH1 and P1, but the difference was smaller (Supporting Fig. S2 ). Together, these results indicate that the cell transcriptome is heterogeneous at the single-cell level.
To determine whether the difference in the singlecell transcriptome reflects its biological nature or is a result of stochastic gene expression at the single-cell level due to low copy transcripts measured by singlecell RNA-seq, we assessed whether potential CSC gene signatures associated with marker-expressing cells are linked to HCC prognosis. We reasoned that if transcriptomic changes in single cells associated with marker expression are functionally important, these changes should be associated with HCC survival, analogous to previous reports using tumor bulk. (16, 25, 27) We first searched for genes that are associated with marker expression by performing a class comparison between triple marker-positive HuH7 cells (CD133 Table S1 ).
Using the 286-gene signature, we performed multivariable Cox regression survival risk prediction analysis with 10-fold cross-validation and 1,000 random permutation of sample labels. We found that the Triple 1 gene signature could predict overall survival in 240 HCC tissues from the LCI cohort (log-rank P < 0.0001), and the cross-validated misclassification rates were significantly lower than expected by chance (permutation P < 0.01) (Fig. 3C) . This relationship was not observed in nontumor tissues from the same LCI cohort (log-rank P > 0.05, permutation P > 0.1) (Fig.  3D) , indicating that the Triple 1 marker signature is tumor-specific. Similar results were observed in the TCGA cohort of 250 HCC cases with available survival data (log-rank P < 0.01, permutation P < 0.05) (Fig. 3E) . Fig. 4A; Supporting Table S1 ). Furthermore, network analysis based on Ingenuity Pathway Analysis revealed that the top networks associated with different marker gene signatures also largely do not overlap, e.g., AKT signaling for CD133 1 cells, nuclear factor kappa B signaling for CD24
Class comparison analysis of distinct CSC subpopulations based on individual markers in HuH7 cells
1 cells, p38 mitogen-activated protein kinase signaling for EpCAM 1 cells, and nuclear factor kappa B for Triple 1 cells, all of which are known canonical signaling pathways critical for maintaining cancer stemness ( Fig. 4C-F ; Supporting Table S2 ). Interestingly, the above marker signatures can predict overall survival of the LCI cohort, the TCGA cohort, and the LEC cohort using multivariable survival risk prediction algorithm described above (Fig. 4B) . Univariable and multivariable Cox regression analysis revealed that gene signatures linked to CD133 and EpCAM, but not CD24, are independent predictors of HCC survival (Supporting Table S3 ). Similar results were obtained in HuH1 cells with borderline significance (Supporting Fig. S2C,E) . These results suggest that, while molecular signaling differs among different marker-expressing cells, marker expression signatures are associated with HCC prognosis. Taken together, the above results indicate that single-cell transcriptome analysis provides sufficient sensitivity to capture biologically relevant molecular signaling linked to distinct functional composition of CSCs and that significant molecular heterogeneity exists among individual tumor cells within a tumor cell community or among different tumor types.
TRANSCRIPTOMIC LANDSCAPES OF HCC CELL COMMUNITY, HETEROGENEITY, AND HCC PROGNOSIS
We sought to determine global cell population diversity in HuH1, HuH7, and P1 by single-cell RNA-seq using the GemCode technology (103 Genomics), a droplet-based system enabling high cell throughput with 50% cell capture efficiency. (28) We generated transcriptome data from 3,847 single cells from HuH1, HuH7, and P1, which were visualized by tSNE projection (Fig. 5) . Consistent with transcriptome data from single cells with defined marker status, single cells are largely clustered based on their distinct cell types (Fig. 5A) . Furthermore, tSNE and hierarchal clustering analyses revealed that HuH1 had two main branches of cells and HuH7 had four main branches of cells, while P1 had three distinct branches of cells ( Fig. 5A; Supporting Fig. S3A,B) . It is noted that a cell population diversity in HuH1, HuH7, and P1 was similar between marker-expressing cells analyzed by single-cell SMART-seq and unsorted populations analyzed by 103 Genomics (Figs. 3A and  5A; Supporting Fig. S2A ), suggesting that single-cell transcriptomic diversity is an intrinsic nature of each cell type. Interestingly, expression patterns of known CSC markers, such as EpCAM, CD133 (PROM1), cytokeratin 19 (KRT19), and aldehyde dehydrogenase (ALDH1A1), varied greatly among individual cells (Fig. 5B) . Similarly, the expression patterns of several known HCC-specific genes, i.e., AFP, (29) MDK, (30) GPC3, (31) GOLM1, (32) YY1AP1, (33) PLK1, ECT2, and NELFE, (7, 34) whose functions are associated with different aspects of hepatocarcinogenesis, were also heterogeneous within each cell community and among different cell types (Fig. 5C ). No discrete cell cluster with the above markers was noted. Because P1 gave rise to three distinct branches of cells, we examined lineage-specific markers, i.e., Yamanaka factors (KLF4, POU5F1, MYC), stem cell marker (NANOG), leukocyte marker (PTPRC), T cell-specific markers (CD3E, CD8A), and B-cell marker (CD79A) (Fig. 5D ) among these cells. We found that only a few cells express Yamanaka factors, except MYC, which is expressed relatively more abundantly in HuH1 and HuH7 than P1 with notable heterogeneity. One branch of P1 cells expressed T-cell markers, while another branch expressed a B-cell marker, indicating that these are infiltrating leukocytes in HCC specimens. The third branch of P1 cells expressed various tumor markers, suggesting that these are tumor cells ( Fig. 5; Supporting Fig. S3A,B) .
CSC heterogeneity may be responsible for intratumor heterogeneity within each tumor cell population and may contribute to HCC prognosis. To test this hypothesis, we first searched for genes that are correlated with all known HCC CSC genes at the singlecell level. We selected ANPEP, (35) CD44, (36) DLK1, (37) KRT19, (38) EPCAM, (16) PROM1, (25) ICAM1, (39) CD47, (40) LGR5, (41) and SOX9, (42) whose functions have been demonstrated to be necessary for maintaining HCC stemness. Global correlation analysis revealed 45 genes for HuH1 and 1,066 genes for HuH7 as CSC heterogeneity-surrogate gene signatures, referred as H1-HET and H7-HET, respectively. This observation is consistent with the above findings ( Fig. 2A) , which suggests that HuH7 cells are more heterogenous compared to HuH1 cells. We then tested whether H1-HET and H7-HET are associated with survival in the LCI, LEC, and TCGA cohorts, a strategy analogous to the analysis of marker signatures described above. We reasoned that these surrogate-gene signatures should reflect CSC activities and thus predict HCC survival. Consistently, crossvalidated survival risk prediction analyses revealed that both H1-HET and H7-HET could predict overall survival in three independent cohorts, i.e., the LCI, LEC, and TCGA cohorts (Supporting Fig. S3C) . The cross-validated misclassification rates were 
Discussion
Intratumor genomic heterogeneity in various solid tumors has been well documented in recent years. However, it is unclear how such heterogeneity contributes to therapeutic failure and cancer progression. Herein we demonstrate the presence of biological and transcriptomic heterogeneity of CSCs at the single-cell level in HCC. We found evidence of CSC heterogeneity within each distinct CSC cell community, which was identified by different CSC markers. Interestingly, transcriptomic heterogeneity was diminished when a pool of cells was analyzed, suggesting that single-cell analysis is required to fully appreciate the heterogenous nature of each tumor. Our findings are analogous to the results from other human malignancies, which demonstrate that tumors are transcriptomically heterogeneous at the single-cell level. (43) (44) (45) (46) Moreover, we show that CSC marker expression-associated genes are linked to HCC prognosis, suggesting that the diverse transcriptome of a single cell may reflect its tumor biology. These results indicate that a meaningful understanding of intratumor heterogeneity, which reflects the true biological nature of the tumor, should be carried out at the single-cell level, rather than tumor bulk. Thus, our study may provide a feasible approach to study the impact of intratumor heterogeneity in HCC development.
Here, using a combined staining of three established CSC markers, i.e., CD24, CD133, EpCAM, we show that hepatic CSCs are spatially heterogeneous under different culture conditions. Accordingly, our data demonstrate that marker-expressing HCC cells are not randomly distributed, but further efforts are needed to investigate whether certain patterns of hepatic CSC distribution or organization exist and are linked to tumor biology. At a single-cell resolution, we found that different surface maker-defined CSCs are functionally heterogeneous in terms of self-renewal capacity and differentiation potential. Phenotypic heterogeneity of CSCs has been suggested, (47) and recently functional heterogeneity of skin and hematopoietic stem cells has been described. (48) It is of interest to note that HCC CSCs exhibited an altered pattern of selfrenewal heterogeneity when cultured under normoxia or hypoxia, suggesting a biological plasticity of these cells. One could speculate that such an intrinsic plasticity of HCC cells is an important feature for tumor progression, especially when facing different tumor microenvironments. Understanding the underlying mechanism that drives CSC plasticity may help us to understand how such events impact tumor microenvironmental heterogeneity and therapeutic response. (49) A limitation of this study is that the findings are largely based on two HCC cell lines and only one clinical specimen from an HCC patient. Thus, interpretation of CSC heterogeneity may not be generalized without data from additional clinical specimens. In principle, with single-cell resolution, coupled with cost-effective UMI-based approaches to increase throughput, one can classify patients into groups based on the diversity of CSC marker gene expression and predict the response of patients to certain chemotherapies or targeted therapies. Encouragingly, we have now established the logistic pipeline that allows us to acquire high-quality single cells derived from HCC patients who have been enrolled in clinical trials at the National Cancer Institute for single-cell transcriptome analysis. Further studies will be focused on incorporating more patient samples to demonstrate the clinical value of this concept. We have now completed singlecell transcriptome analysis in 20 additional HCC patients using the v2 version of 103 Genomics to determine the degree of molecular distinctiveness among human HCC samples and their relationship with patient outcomes, which is the subject of a new article. Another limitation is that there is no optimization of reads mapped to our samples before sequencing. As a proof-of-concept study, we used all sequencing data available on limited numbers of cells. Future studies will have to balance the cost of sequencing and the number of samples included for analysis. A careful calculation of average reads available for samples should be considered.
In summary, this study highlights the molecular composition and heterogeneity of CSCs in HCC, which may be used for CSC targeting strategies. Furthermore, evaluation of CSC heterogeneity and its prognostic value based on single-cell transcriptome data provides new insight into intratumor heterogeneity, tumor progression, and their implications in the clinical setting.
